PMID- 36115921
OWN - NLM
STAT- MEDLINE
DCOM- 20230321
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 72
IP  - 4
DP  - 2023 Apr
TI  - Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression 
      patterns of HLA class I on the prognosis of patients with malignant pleural 
      mesothelioma who underwent extra-pleural pneumonectomy.
PG  - 865-879
LID - 10.1007/s00262-022-03292-4 [doi]
AB  - Programmed cell death protein-1 (PD1), PD1 ligand 1 (PD-L1), and human leukocyte 
      antigen (HLA) class I molecule play pivotal roles in T cell-induced anti-tumor 
      immunity; however, the clinical impact of these parameters in resected malignant 
      pleural mesothelioma (MPM) cases is unknown. We immunohistochemically evaluated 
      the tumor infiltrated lymphocytes (TILs), PD1/PD-L1 axis, and expression of HLA 
      class I in resected specimens from 58 patients with MPM who underwent 
      extra-pleural pneumonectomy (EPP). Higher infiltration of CD3-TIL, CD8-TIL, and 
      PD1-TIL, loss of HLA class I, and overexpression of PD-L1 by tumor cells (PD-L1 
      TC) or immune cells (PD-L1 IC) were observed in 34 (58.6%), 27 (46.6%), 41 
      (70.7%), 45 (77.6%), 29 (50.0%), and 33 (56.4%) of 58 cases, respectively. 
      Interestingly, the CD3-TIL score positively correlated with PD-L1 TC and PD1-TIL 
      scores. HLA class I expression level was inversely correlated with the expression 
      levels of PD-L1 TC and PD-L1 IC. Multivariate analysis showed that age, 
      histology, and node metastasis were independent prognostic factors for 5-year 
      overall survival (OS) and loss of HLA class I coincided with a positive prognosis 
      (p = 0.011). The concomitant lack of infiltrating CD8+ T cells with no loss of 
      HLA class I predicted worse 5-year OS (p = 0.007). Moreover, cluster 
      classifications among multiple immunoparameters showed that categories among 
      CD3/PD-L1 TC/HLA class I (p = 0.043), CD8/PD1/HLA class I (p = 0.032), CD8/PD-L1 
      TC/HLA class I (p = 0.011), and PD1/PD-L1 TC/HLA class I (p = 0.032) predicted 
      5-year OS in EPP cases for MPM. These immunoparameters could guide surgical 
      indications for patients with MPM.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Okita, Riki
AU  - Okita R
AUID- ORCID: 0000-0003-1343-1275
AD  - Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan. 
      riki0716okita@yahoo.co.jp.
FAU - Mimura-Kimura, Yuka
AU  - Mimura-Kimura Y
AD  - Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, 
      Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
FAU - Kawamoto, Nobutaka
AU  - Kawamoto N
AUID- ORCID: 0000-0002-4340-0894
AD  - Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
FAU - Yamamoto, Naoki
AU  - Yamamoto N
AD  - Gastroenterology and Hepatology, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
AD  - Department of Gastroenterology and Hepatology, Yamaguchi Health Administration 
      Center, Yamaguchi University Graduate School of Medicine, Minami Kogushi 1-1-1, 
      Ube, Yamaguchi, 755-8505, Japan.
FAU - Umeda, Masashi
AU  - Umeda M
AD  - Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
FAU - Okada, Masanori
AU  - Okada M
AD  - Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
FAU - Inokawa, Hidetoshi
AU  - Inokawa H
AD  - Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
FAU - Mimura, Yusuke
AU  - Mimura Y
AD  - Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, 
      Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
FAU - Murakami, Tomoyuki
AU  - Murakami T
AD  - Clinical Research, National Hospital Organization Yamaguchi Ube Medical Center, 
      Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
AD  - Department of Pathology, National Hospital Organization Kanmon Medical Center, 
      Chofusotoura-cho 1-1, Shimonoseki, Yamaguchi, 752-8510, Japan.
FAU - Nakata, Masao
AU  - Nakata M
AD  - Department of General Thoracic Surgery, Kawasaki Medical School, Matsushima 577, 
      Kurashiki, 7010192, Japan.
FAU - Okabe, Kazunori
AU  - Okabe K
AD  - Department of Thoracic Surgery, National Hospital Organization Yamaguchi Ube 
      Medical Center, Higashikiwa 685, Ube, Yamaguchi, 755-0241, Japan.
AD  - Department of Thoracic Surgery, Bell Land General Hospital, Higashiyama 500-3, 
      Nakaku, Sakai, Osaka, 599-8247, Japan.
LA  - eng
GR  - 16K10696/Japan Society for the Promotion of Science/
GR  - 19K09298/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20220917
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Ligands)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Humans
MH  - *Mesothelioma, Malignant/pathology
MH  - B7-H1 Antigen/metabolism
MH  - Pneumonectomy
MH  - Ligands
MH  - Lymphocytes, Tumor-Infiltrating
MH  - Prognosis
MH  - CD8-Positive T-Lymphocytes
MH  - Histocompatibility Antigens Class I
PMC - PMC10991632
OTO - NOTNLM
OT  - Human leukocyte antigen class I (HLA class I)
OT  - Malignant pleural mesothelioma (MPM)
OT  - Prognostic factor
OT  - Programmed cell death protein-1/programmed cell death protein-1 ligand 1 axis 
      (PD1/PD-L1 axis)
OT  - Tumor microenvironment (TME)
COIS- Dr. Masao Nakata received research funding from Nihon Medi-Physics Co., Ltd., 
      Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly 
      Japan K.K. for research outside the scope of the submitted work. All other 
      authors declare no competing interests.
EDAT- 2022/09/18 06:00
MHDA- 2023/03/22 06:00
PMCR- 2022/09/17
CRDT- 2022/09/17 23:22
PHST- 2022/01/31 00:00 [received]
PHST- 2022/09/05 00:00 [accepted]
PHST- 2022/09/18 06:00 [pubmed]
PHST- 2023/03/22 06:00 [medline]
PHST- 2022/09/17 23:22 [entrez]
PHST- 2022/09/17 00:00 [pmc-release]
AID - 10.1007/s00262-022-03292-4 [pii]
AID - 3292 [pii]
AID - 10.1007/s00262-022-03292-4 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2023 Apr;72(4):865-879. doi: 
      10.1007/s00262-022-03292-4. Epub 2022 Sep 17.